Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study

Area of Science:

• Urology
• Endocrinology
• Pharmacology

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men.
• Current treatments for BPH have limitations and side effects.
• Progesterone compounds have been investigated for potential BPH therapeutic effects.

Purpose of the Study:

• To evaluate the efficacy of 17-alpha-hydroxyprogesterone 17-n-caproate (Primostat) in treating benign prostatic hyperplasia.
• To compare the effects of the progesterone compound against a placebo in patients with BPH.

Main Methods:

• A placebo-controlled study involving 39 patients diagnosed with benign prostatic hyperplasia.
• Objective measurements included residual urine volume, prostatic size, and histological/ultrastructural analysis of prostate tissue.
• Hormonal levels (luteinizing hormone, follicle-stimulating hormone, estrogen) and subjective voiding patterns were assessed.

Main Results:

• Statistical analysis revealed no significant objective improvement in patients treated with 17-alpha-hydroxyprogesterone 17-n-caproate compared to placebo.
• No significant differences were observed in residual urine, prostatic size, or histological/ultrastructural changes.
• While some subjective improvements in voiding were reported, they were not statistically substantiated.

Conclusions:

• 17-alpha-hydroxyprogesterone 17-n-caproate demonstrated no significant efficacy in treating benign prostatic hyperplasia based on objective parameters.
• Potential subjective benefits might be linked to a beta-adrenergic response, but require further investigation.
• The study highlights the importance of rigorous controls, statistical analysis, and patient follow-up in BPH research.